Tetraspanin family member CD9 inhibits Aggrus/podoplanin-induced platelet aggregation and suppresses pulmonary metastasis

Blood

Volumn 112, Issue 5, 2008, Pages 1730-1739

  Nakazawa, Youya ^a,b   Sato, Shigeo ^a   Naito, Mikihiko ^b   Kato, Yukinari ^c   Mishima, Kazuhiko ^d   Arai, Hiroyuki ^b   Tsuruo, Takashi ^a   Fujita, Naoya ^a  

^a CANCER INSTITUTE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

^d SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD9 ANTIGEN; MEMBRANE PROTEIN; PODOPLANIN; TETRASPANIN; LEUKOCYTE ANTIGEN; MULTIPROTEIN COMPLEX; PDPN PROTEIN, HUMAN; RECOMBINANT PROTEIN; T1A 2 PROTEIN, HUMAN; T1A-2 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOPRECIPITATION; LUNG METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN INTERACTION; PROTEIN LOCALIZATION; THROMBOCYTE AGGREGATION; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; CHO CELL; CRICETULUS; GENETIC TRANSFECTION; GENETICS; HAMSTER; LUNG TUMOR; METABOLISM; METASTASIS; MOUSE MUTANT; NUDE MOUSE; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD; CELL LINE, TUMOR; CHO CELLS; CRICETINAE; CRICETULUS; FEMALE; HUMANS; LUNG NEOPLASMS; MEMBRANE GLYCOPROTEINS; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; MICE, NUDE; MICE, SCID; MULTIPROTEIN COMPLEXES; PLATELET AGGREGATION; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; TRANSFECTION;

EID: 52649170765     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-11-124693     Document Type: Article

References (54)

1. Hemler ME. Tetraspanin proteins mediate cellular penetration, invasion and fusion events, and define a novel type of membrane microdomain. Annu Rev Cell Dev Biol. 2003;19:397-422.
2. Hemler ME. Tetraspanin functions and associated microdomains. Nat Rev Mol Cell Biol. 2005;6: 801-811.
3. Miyake M, Koyama M, Seno M, Ikeyama S. Identification of the motility-related protein (MRP-1), recognized by monoclonal antibody M31-15. which inhibits cell motility. J Exp Med. 1991;174: 1347-1354.
4. Higashiyama M, Doi O, Kodama K, et al. Immunohistochemically detected expression of motilityrelated protein-1 (MRP-1/CD9) in lung adenocarcinoma and its relation to prognosis. Int J Cancer. 1997;74:205-211.
5. Miyamoto S. Maruyama A, Okugawa K, et al. Loss of motility-related protein 1 (MRP1/CD9) and integrin α3 expression in endometrial cancers. Cancer. 2001;92:542-548.
6. Hashida H, Takabayashi A, TokuharaT, et al. Integrin α3 expression as a prognostic factor in colon cancer: association with M RP-1/CD9 and KAI1/CD82. IntJ Cancer. 2002;97:518-525.
7. Miyake M, Nakano K, leki Y et al. Motility related protein 1 (MRP-1/CD9) expression: inverse correlation with metastases in breast cancer. Cancer Res. 1995;55:4127-4131.
8. Huang CI, Kohno N, Ogawa E, Adachi M. Taki T, Miyake M. Correlation of reduction in MRP-1/CD9 and KAI1/CD82 expression with recurrences in breast cancer patients. Am J Pathol. 1998;153: 973-983.
9. Cajot JF, Sordat I, Silvestre T, Sordat B. Differential display cloning identifies motility-related protein (MRP1/CD9) as highly expressed in primary compared to metastatic human colon carcinoma cells. Cancer Res. 1997;57:2593-2597.
10. Higashiyama M, Taki T, leki Y, et al. Reduced motility related protein-1 (MRP-1/CD9) gene expression as a factor of poor prognosis in non-small cell lung cancer. Gancer Res. 1995;55:6040-6044.
11. Miyake M, Nakano K, Itoi SI, Koh T, Taki T. Motility-related protein-1 (MRP-1/CD9) reduction as a factor of poor prognosis in breast cancer. Cancer Res. 1996;56:1244-1249.
12. Miyake M, Adachi M, Huang C, Higashiyama M, Kodama K, Taki T. A novel molecular staging protocol for non-small cell lung cancer. Oncogene. 1999;18:2397-2404.
13. Takeda T, Hattori N, Tokuhara T, Nishimura Y, Yokoyama M, Miyake M. Adenoviral transduction of MRP-1/CD9 and KAI1/CD82 inhibits lymph node metastasis in orthotopic lung cancer model. Cancer Res. 2007:67:1744-1749.
14. Zvieriev V, Wang JC, Chevrette M. Over-expression of CD9 does not affect in vivo tumorigenic or metastatic properties of human prostate cancer cells. Biochem Biophys Res Commun. 2005;337:498-504.
15. Sauer G, Windisch J, Kurzeder C, Heilmann V, Kreienberg R, Deissler H. Progression of cervical carcinomas is associated with downregulation of CD9 but strong local re-expression at sites of transendothelial invasion. Clin Cancer Res. 2003; 9:6426-6431.
16. Martin-Villar E, Scholl FG, Gamallo C, et al. Characterization of hu man PA2.26 antigen (T1α-2, podoplanin), a small membrane mucin induced in oral squamous cell carcinomas. Int J Cancer. 2005;113:899-910.
17. Kato Y, Kaneko M, Sata M, Fujita N, Tsuruo T, Osawa M. Enhanced expression of Aggrus (T1α/podoplanin), a platelet-aggregation-inducing factor in lung squamous cell carcinoma. Tumour Biol. 2005;26:195-200.
18. Schacht V. Dadras SS. Johnson LA, Jackson DG, Hong YK, Detmar M. Upregulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors. Am J Pathol. 2005;166:913-921.
19. Kimura N. Kimura I. Podoplanin as a marker for mesothelioma. Pathol Int. 2005;55:83-86.
20. Kato Y, Sasagawa I, Kaneko M, Osawa M, Fujita N, Tsuruo T. Aggrus: A diagnostic marker that distinguishes seminoma from embryonal carcinoma in testicular germ cell tumors. Oncogene. 2004; 23:8552-8556.
21. Shibahara J, Kashima T, Kikuchi Y, Kunita A, Fukayama M. Podoplanin is expressed in subsets of tumors of the central nervous system. Virchows Arch. 2006;448:493-499.
22. Mishima K, Kato Y Kaneko MK, Nishikawa R, Hirose T, Matsutani M. Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression. Acta Neuropathol. 2006;111:483-488.
23. Mishima K, Kato Y, Kaneko MK, et al. Podoplanin expression in primary central nervous system germ cell tumors: a useful histological marker for the diagnosis of germinoma. Acta Neuropathol. 2006:111:563-568.
24. Yuan P, Temam S, EI-Naggar A, et al. Overexpression of podoplanin in oral cancer and its association with poor clinical outcome. Cancer. 2006;107:563-569.
25. Wicki A, Lehembre F, Wick N, Hantusch B, Kerjaschki D, Christofori G. Tumor invasion in the absence of epithelial-mesenchymal transition: podoplanin-mediated remodeling of the actin cytoskeleton. Cancer Cell. 2006;9:261-272.
26. Kato Y, Fujita N, Kunita A, et al. Molecular identification of Aggrus/T1α as a platelet aggregationinducing factor expressed in colorectal tumors. J Biol Chem. 2003;278:51599-51605.
27. Kunita A, Kashima TG, Morishita Y et al. The platelet aggregation-inducing factor aggrus/podoplanin promotes pulmonary metastasis. Am J Pathol. 2007;170:1337-1347.
28. Suzuki-lnoue K, Kato Y, Inoue O, et al. Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet activation, by cancer cells. J Biol Chem. 2007;282:25993-26001.
29. Christou CM, Pearce AC, Watson AA, et al. Renal cells activate the platelet receptor CLEC-2 through podoplanin. Biochem J. 2008;411:133-140.
30. Suzuki-lnoue K, Fuller GL, Garcfa A, et al. A novel Syk-dependent mechanism of platelet activation by the C-type lectin receptor CLEC-2. Blood. 2006;107:542-549.
31. Malik AB. Pulmonary microembolism. Physiol Rev. 1983;63:1114-1207.
32. Fidler IJ. Metastasis: guantitative analysis of distribution and fate of tumor emboli labeled with 125 l-5-iodo-2'-deoxyuridine. J Natl Cancer Inst. 1970;45:773-782.
33. Philippe C, Philippe B, Fouqueray B, Perez J, Lebret M, Baud L. Protection from tumor necrosis factor-mediated cytolysis by platelets. Am J Pathol. 1993;143:1713-1723.
34. Camerer E, Qazi AA, Duong DN, Cornelissen I, Advincula R, Coughlin SR. Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis. Blood. 2004;104:397-401.
35. Claas C, Stipp CS, Hemler ME. Evaluation of prototype transmembrane 4 superfamily protein complexes and their relation to lipid rafts. J Biol Chem. 2001;276:7974-7984.
36. Ikeyama S, Koyama M, Yamaoko M, Sasada R, Miyake M. Suppression of cell motility and metastasis by transfection with human motility-related protein (MRP-1/CD9) DNA. J Exp Med. 1993; 177:1231-1237.
37. Miyake M, Inufusa H, Adachi M, et al. Suppression of pulmonary metastasis using adenovirally motility related protein-1 (MRP-1/CD9) gene delivery. Oncogene. 2000;19:5221-5226.
38. Zheng R, Yano S, Zhang H. et al. CD9 overexpression suppressed the liver metastasis and malignant ascites via inhibition of proliferation and motility of small-cell lung cancer cells in NK celldepleted SCID mice. Oncol Res. 2005;15:365-372.
39. Ono M, Handa K, Withers DA, Hakomori S. Motility inhibition and apoptosis are induced by metastasis-suppressing gene product CD82 and its analogue CD9, with concurrent glycosylation. Cancer Res. 1999;59:2335-2339.
40. Funakoshi T Tachibana I, Hoshida Y, et al. expression of tetraspanins in human lung cancer cells: frequent downregulation of CD9 and its contribution to cell motility in small cell lung cancer. Oncogene. 2003;22:674-687.
41. Liu J, Fitzgerald ME, Berndt MC, Jackson CW, Gartner TK. Bruton tyrosine kinase is essential for botrocetin/VWF-induced signaling and GPIbdependent thrombus formation in vivo. Blood. 2006:108:2596-2603.
42. Vijayan KV, Liu Y, Sun W, Ito M, Bray PF. The Pro33 isoform of integrin beta3 enhances outside-in signaling in human platelets by regulating the activation of serine/threonine phosphatases. J Biol Chem. 2005;280:21756-21762.
43. Kovalenko OV, Metcalf DG, DeGrado WF, Hemler ME. Structural organization and interactions of transmembrane domains in tetraspanin proteins. BMC Struct Biol. 2005;5:11.
44. Bandyopadhyay S, Zhan R, Chaudhuri A, et al. Interaction of KAI1 on tumor cells with DARC on vascular endothelium leads to metastasis suppression. Nat Med. 2006;12:933-938.
45. Baudoux B, Castanares-Zapatero D. Leclercq-Smekens M, Berna N, Poumay Y. The tetraspanin CD9 associates with the integrin α6β4 in cultured human epidermal keratinocytes and is involved in cell motility. Eur J Cell Biol. 2000;79:41-51.
46. Janowska-Wieczorek A, Wysoczynski M, Kijowski J, et al. Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. Int J Cancer. 2005;113:752-760.
47. Boucharaba A, Serre CM, Gres S, et al. Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J Clin Invest. 2004;114:1714-1725.
48. Nierodzik ML, Karpatkin S. Thrombin induces tumor growth, metastasis, and angiogenesis: Evidence for a thrombin-regulated dormant tumor phenotype. Cancer Cell. 2006:10:355-362.
49. r 44,000 membrane protein as determined by monoclonal antibodies. Cancer Res. 1988;48:6411-6416.
50. Amirkhosravi A, Mousa SA, Amaya M, et al. Inhibition of tumor cell-induced platelet aggregation and lung metastasis by the oral Gpllb/I I la antagonist XV454. Thromb Haemost. 2003;90:549-554.
51. Borsig L, Wong R, Feramisco J, Nadeau DR, Varki NM, Varki A. Heparin and cancer revisited: mechanistic connections involving platelets, Pselectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci U S A. 2001;98:3352-3357.
52. Stevenson JL, Choi SH, Varki A. Differential metastasis inhibition by clinically relevant levels of heparins-correlation with selectin inhibition, not antithrombotic activity. Clin Cancer Res. 2005;11: 7003-7011.
53. Kaser A, Brandacher G, SteurerW, et al. lnterleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis. Blood. 2001;98:2720-2725.
54. Falanga A, Ofosu FA, Delaini F, et al. The hypercoagulable state in cancer patients: evidence for impaired thrombin inhibitions. Blood Coagul Fibrinolysis. 1994;5:59-64.